SOURCE:

https://www.phmpt.org/wp-content/uploads/2022/04/reissue_5.3.6-postmarketing-experience.pdf

Pfizer had 1,002 case reports in the anaphylaxis category, or 2.4% of the total 42,086 adverse event patients from all causes. They categorized anaphylaxis under “Important identified risks.” Anaphylaxis is generally considered a medical emergency. In this report, **79% of the events were considered serious**. In spite of anaphylaxis being treatable, it remains a potentially fatal condition as demonstrated by the **nine deaths** reported.

Pfizer noted that four of the patients who died had “serious underlying medical conditions” that “likely contributed to their deaths.” **Adverse events in the high-risk patients offset the potential benefits of the immunization and must be part of the consideration for approval**. Of course, those who are medically fragile will be at greater risk with any adverse event.

Females comprised 89% of the anaphylaxis reports compared to 77% of the total cases in the post-authorization compilation. There is no comment from Pfizer on the marked female predominance in this adverse event category, let alone any stated plan to address it.

Pfizer’s Conclusion:

Evaluation of BC *(Brighton Collaborative)* cases Level 1 - 4 did not reveal any significant new safety information. Anaphylaxis is appropriately described in the product labeling as are non-anaphylactic hypersensitivity events. Surveillance will continue.

Post-Marketing Team’s CONCLUSION

RECALL this unsafe “vaccine.”

Post Marketing Team